2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1994

Helicobacter Pylori Infection Among Korean Patients with Rheumatoid Arthritis and Its Interaction with Shared Epitope
Abstract Number: 1995

Gingival-Derived Mesenchymal Stem Cells Alleviate Cartilage Damage in Collagen-Induced Arthritis via Suppressing Activities of Inflamed Synovial Fibroblast
Abstract Number: 1996

Bromodomain Inhibitor, I-BET762 Inhibits Production of Pro-inflammatory in Rheumatoid Arthritis Fibroblast-like Synoviocytes and Differentiation of Osteoclast
Abstract Number: 1997

Histologic and Clinical Correlates of Ultrasound Measures of Joint Inflammation: Analysis of RA Tissue Obtained by Ultrasound Guided Biopsy in Phase 2 of the Accelerating Medicines Partnership RA Network
Abstract Number: 1998

Major Histocompatibility Antigen HLA-DQB1*0601 Is Associated with Rheumatoid Arthritis Among Indians in a Replication Study: Evidence of Gene-Environment Interaction with LPG Stove Use
Abstract Number: 1999

NADPH Oxidase 4 Regulates the Migration and Invasion of Synoviocytes in Rheumatoid Arthritis Through Pro-angiogenic Factor Secretion
Abstract Number: 2000

Anti-inflammatory Effect of Novel Spleen Tyrosine Kinase Inhibitor, SKI-O-592, on Fibroblast-like Synoviocyte in Rheumatoid Arthritis and THP-1 Cell
Abstract Number: 2001

Survivin Controls the Transcriptional Activity by Changing the Pattern of Histone H3 Marks on Chromatin
Abstract Number: 2002

Presence of the MerTK Receptor on Human Synovial Tissue Macrophages Lowers Inflammatory Cytokine Production and Activation of the MerTK+CD206+ Subpopulation Limits the Inflammatory Response of Synovial Fibroblasts
Abstract Number: 2003

Anti-Polygalacturonic Acid Antibody (PGA-Ab) Induced Bone Destruction in Rheumatoid Arthritis by Promoting Osteoclastogenesis via Integrin Beta 5
Abstract Number: 2004

Protein Profiling and Network Enrichment Analysis in Individuals Before and After the Onset of Rheumatoid Arthritis
Abstract Number: 2005

Circulating Mitochondrial Danger-Associated Molecular Patterns as Novel Biomarkers of Disease Activity and Inflammation in Rheumatoid Arthritis
Abstract Number: 2006

Pyruvate Kinase M2 May Contribute to the Inflammation and Joint Destruction in Rheumatoid Arthritis
Abstract Number: 2007

Periodontal Pockets as a Potential Source of Circulating TREM-1 and Its Ligand PGLYRP1 in Patients with Rheumatoid Arthritis
Abstract Number: 2008

Histone Lysine Methyltransferase MLL1 Regulates the Expression of Cytokines and Chemokines in Rheumatoid Arthritis Synovial Fibroblasts

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].